ReviewCureus2026
Phyllodes Tumors of the Breast in 2026: A Contemporary Narrative Review of Diagnosis, Surgical Margins, Prognosis, and Emerging Therapies.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phyllodes tumors of the breast are rare fibroepithelial neoplasms characterized by significant heterogeneity regarding morphology, biological behavior, and clinical outcome. This review summarizes current developments in the diagnosis, histopathological and molecular classification, therapeutic management, and emerging technologies associated with phyllodes tumors of the breast. A literature search was conducted across PubMed/MEDLINE, Scopus, Embase, and Google Scholar, focusing on publications from the 2000-2026 period. The literature search covered publications from January 1, 2000, to September 30, 2026, and was last updated on September 30, 2026. Mammography, ultrasound, and magnetic resonance imaging contribute to preoperative assessment, although significant diagnostic overlap with fibroadenomas persists. Core needle biopsy is a key diagnostic tool, yet lesion heterogeneity can limit the accuracy of histological classification. Advances in molecular pathology have identified mutations and pathways associated with the progression and aggressiveness of phyllodes tumors, though these have not yet replaced morphological assessment. Surgical excision with negative margins remains the primary therapeutic approach, while the risk of local recurrence depends on histological grade, surgical margins, and other clinicopathological characteristics. Radiotherapy in phyllodes tumors of the breast appears to offer benefits primarily regarding local control in selected high-risk cases. Emerging technologies, including artificial intelligence, radiomics, and digital pathology, are proving to be promising tools for diagnosis, grading, and prognostic assessment. Overall, modern management of phyllodes tumors of the breast is shifting toward more personalized and multifactorial approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.